Eleven Biotherapeutics Company Profile (NASDAQ:EBIO)

About Eleven Biotherapeutics (NASDAQ:EBIO)

Eleven Biotherapeutics logoEleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company's product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis. The Company's therapeutic approach is based on the role of cytokines in diseases of the eye, its understanding of the structural biology of cytokines and its ability to design and engineer proteins to modulate the effects of cytokines. The Company is developing EBI-031 as an intravitreal injection for DME and uveitis. In addition to EBI-031, the Company has another product candidate in early preclinical development, which is designed to block vascular endothelial growth factor (VEGF).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:EBIO
  • CUSIP: N/A
  • Web: www.elevenbio.com
Capitalization:
  • Market Cap: $38.29 million
  • Outstanding Shares: 15,393,000
Average Prices:
  • 50 Day Moving Avg: $1.51
  • 200 Day Moving Avg: $1.83
  • 52 Week Range: $1.31 - $5.97
P/E:
  • Trailing P/E Ratio: 10.430
  • Foreward P/E Ratio: Infinity
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: $30.18 million
  • Price / Sales: 0.80
  • Book Value: $1.33 per share
  • Price / Book: 1.18
Profitability:
  • EBIDTA: $8.26 million
  • Net Margins: 11.28%
  • Return on Equity: 7.73%
  • Return on Assets: 3.16%
Debt:
  • Current Ratio: 6.52%
  • Quick Ratio: 6.52%
Misc:
  • Average Volume: 257,324 shs.
  • Beta: 3.37
  • Short Ratio: 5.2
 
Frequently Asked Questions for Eleven Biotherapeutics (NASDAQ:EBIO)

What is Eleven Biotherapeutics' stock symbol?

Eleven Biotherapeutics trades on the NASDAQ under the ticker symbol "EBIO."

How were Eleven Biotherapeutics' earnings last quarter?

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) posted its quarterly earnings results on Thursday, May, 4th. The company reported ($0.25) EPS for the quarter. The business earned $0.43 million during the quarter. Eleven Biotherapeutics had a return on equity of 7.73% and a net margin of 11.28%. View Eleven Biotherapeutics' Earnings History.

Who are some of Eleven Biotherapeutics' key competitors?

Who are Eleven Biotherapeutics' key executives?

Eleven Biotherapeutics' management team includes the folowing people:

  • Daniel S. Lynch, Chairman of the Board
  • Stephen A. Hurly, President, Chief Executive Officer, Director
  • John J McCabe, Principal Financial Officer, Principal Accounting Officer
  • Glen C. MacDonald Ph.D., Chief Scientific Officer
  • Gregory P. Adams Ph.D., Chief Development Officer
  • Arthur P. DeCillis M.D., Chief Medical Officer
  • Abbie C. Celniker Ph.D., Director
  • Paul G. Chaney, Director
  • Wendy L. Dixon Ph.D., Director
  • Jay S. Duker MD., Director

How do I buy Eleven Biotherapeutics stock?

Shares of Eleven Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eleven Biotherapeutics' stock price today?

One share of Eleven Biotherapeutics stock can currently be purchased for approximately $1.58.


MarketBeat Community Rating for Eleven Biotherapeutics (NASDAQ EBIO)
Community Ranking:  2.2 out of 5 ( )
Outperform Votes:  31 (Vote Outperform)
Underperform Votes:  41 (Vote Underperform)
Total Votes:  72
MarketBeat's community ratings are surveys of what our community members think about Eleven Biotherapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Eleven Biotherapeutics (NASDAQ:EBIO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Eleven Biotherapeutics (NASDAQ:EBIO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
1/19/2016Citigroup Inc.DowngradeBuy -> NeutralN/AView Rating Details
1/18/2016Leerink SwannDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 7/27/2015 forward)

Earnings

Earnings History for Eleven Biotherapeutics (NASDAQ:EBIO)
Earnings by Quarter for Eleven Biotherapeutics (NASDAQ:EBIO)
Earnings History by Quarter for Eleven Biotherapeutics (NASDAQ EBIO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.25)$0.43 millionViewListenView Earnings Details
3/24/2017Q4 2016($0.12)($0.20)$0.83 millionViewN/AView Earnings Details
11/14/2016Q3($0.17)$0.91$28.70 millionViewListenView Earnings Details
8/12/2016Q2($0.33)$0.28 millionViewN/AView Earnings Details
3/24/2016Q4($0.32)($0.53)$0.57 millionViewN/AView Earnings Details
11/4/2015Q315($0.44)($0.50)$0.10 million$0.07 millionViewListenView Earnings Details
8/13/2015Q215($0.43)($0.36)$0.20 million$0.11 millionViewListenView Earnings Details
4/30/2015Q115($0.57)($0.36)$0.20 million$0.24 millionViewListenView Earnings Details
3/4/2015Q414($0.33)($0.49)$0.80 million$0.38 millionViewListenView Earnings Details
11/13/2014Q314($0.45)($0.66)$0.70 million$0.54 millionViewN/AView Earnings Details
8/13/2014Q2 2014($0.47)($0.51)$0.10 million$0.76 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Eleven Biotherapeutics (NASDAQ:EBIO)
Current Year EPS Consensus Estimate: $-1.85 EPS

Dividends

Dividend History for Eleven Biotherapeutics (NASDAQ:EBIO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Eleven Biotherapeutics (NASDAQ:EBIO)
Insider Ownership Percentage: 28.70%
Institutional Ownership Percentage: 9.72%
Insider Trades by Quarter for Eleven Biotherapeutics (NASDAQ:EBIO)
Institutional Ownership by Quarter for Eleven Biotherapeutics (NASDAQ:EBIO)
Insider Trades by Quarter for Eleven Biotherapeutics (NASDAQ:EBIO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/28/2016Abbie CelnikerDirectorSell10,031$3.00$30,093.00View SEC Filing  
9/23/2016Ventures Fund 2007 L FlagshipMajor ShareholderSell443,422$3.16$1,401,213.52View SEC Filing  
9/21/2016Ventures Fund Iv L.P FlagshipMajor ShareholderSell322,723$3.75$1,210,211.25View SEC Filing  
9/20/2016Ventures Fund Iv L.P FlagshipMajor ShareholderSell53,917$3.39$182,778.63View SEC Filing  
9/19/2016Ventures Fund Iv L.P FlagshipMajor ShareholderSell9,700$3.31$32,107.00View SEC Filing  
9/15/2016Ventures Fund 2007 L FlagshipMajor ShareholderSell46,692$4.18$195,172.56View SEC Filing  
9/7/2016Ventures Fund 2007 L FlagshipMajor ShareholderSell129,497$4.54$587,916.38View SEC Filing  
8/15/2016John J MccabeCFOSell1,170$4.80$5,616.00View SEC Filing  
6/27/2016Abbie CelnikerCEOSell10,029$2.08$20,860.32View SEC Filing  
6/27/2016Karen L TubridyInsiderSell4,372$2.08$9,093.76View SEC Filing  
6/13/2016Boxer Capital, LlcMajor ShareholderSell1,042,000$2.74$2,855,080.00View SEC Filing  
2/16/2016John J MccabeSVPSell1,501$0.27$405.27View SEC Filing  
12/28/2015Abbie CelnikerCEOSell10,155$2.85$28,941.75View SEC Filing  
12/28/2015Eric Steven FurfineInsiderSell4,652$2.85$13,258.20View SEC Filing  
5/8/2015Jafco Super V3 Investment LimiMajor ShareholderSell33,400$13.23$441,882.00View SEC Filing  
2/2/2015Jafco Super V3 Investment LimiMajor ShareholderSell17,900$11.62$207,998.00View SEC Filing  
1/30/2015Jafco Super V3 Investment LimiMajor ShareholderSell120,000$11.62$1,394,400.00View SEC Filing  
1/26/2015Jafco Super V3 Investment LimiMajor ShareholderSell6,300$11.85$74,655.00View SEC Filing  
1/22/2015Jafco Super V3 Investment LimiMajor ShareholderSell6,300$11.82$74,466.00View SEC Filing  
1/16/2015Jafco Super V3 Investment LimiMajor ShareholderSell6,100$12.07$73,627.00View SEC Filing  
8/26/2014Jafco Super V3 Investment LimiMajor ShareholderSell2,000$11.54$23,080.00View SEC Filing  
8/20/2014Jafco Super V3 Investment LimiMajor ShareholderSell1,165$11.54$13,444.10View SEC Filing  
8/18/2014Jafco Super V3 Investment LimiMajor ShareholderSell2,600$11.81$30,706.00View SEC Filing  
8/14/2014Jafco Super V3 Investment LimiMajor ShareholderSell2,000$11.75$23,500.00View SEC Filing  
2/11/2014Jafco Super V3 Investment LimiMajor ShareholderBuy219,790$10.00$2,197,900.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Eleven Biotherapeutics (NASDAQ:EBIO)
Latest Headlines for Eleven Biotherapeutics (NASDAQ:EBIO)
Source:
DateHeadline
prnewswire.com logoToday's Research Report Coverage on Biotech Stocks -- Eleven Biotherapeutics, Egalet, Aevi Genomic Medicine, and ... - PR Newswire (press release)
www.prnewswire.com - July 18 at 7:38 PM
finance.yahoo.com logoETFs with exposure to Eleven Biotherapeutics, Inc. : July 13, 2017
finance.yahoo.com - July 13 at 7:26 PM
seekingalpha.com logoEleven Biotherapeutics (EBIO) Presents At 2017 Marcum Microcap Conference - Slideshow
seekingalpha.com - June 20 at 12:38 AM
americanbankingnews.com logoEleven Biotherapeutics, Inc. (EBIO) Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - June 13 at 4:04 PM
finance.yahoo.com logoEleven Biotherapeutics to Present at 2017 Marcum MicroCap Conference
finance.yahoo.com - June 12 at 5:46 PM
streetinsider.com logoEleven Biotherapeutics (EBIO) to Partner with AstraZeneca (AZN) & National Cancer Institute on Development of ... - StreetInsider.com
www.streetinsider.com - June 6 at 10:16 PM
finance.yahoo.com logoEleven Biotherapeutics to Collaborate with AstraZeneca and the National Cancer Institute on Development of ViciniumTM in Combination with Durvalumab for the Treatment of Non-Muscle Invasive Bladder Cancer
finance.yahoo.com - June 6 at 5:15 PM
businesswire.com logoEleven Biotherapeutics Announces Data and Safety Monitoring Board (DSMB) Recommendation to Continue Phase 3 Registration Trial with Vicinium™ in Non-Muscle Invasive Bladder ...
www.businesswire.com - June 2 at 4:19 PM
streetinsider.com logoEleven Biotherapeutics (EBIO) Report Data & Safety Monitoring Board Recommendation to Continue Phase 3 ... - StreetInsider.com
www.streetinsider.com - June 1 at 5:36 PM
streetinsider.com logoEleven Biotherapeutics (EBIO) Report Data & Safety Monitoring Board Recommendation to Continue Phase 3 ... - StreetInsider.com
www.streetinsider.com - June 1 at 5:36 PM
finance.yahoo.com logoEleven Biotherapeutics Announces Data and Safety Monitoring Board (DSMB) Recommendation to Continue Phase 3 Registration Trial with Vicinium™ in Non-Muscle Invasive Bladder Cancer Based on Review of Safety and Efficacy Data
finance.yahoo.com - June 1 at 5:36 PM
finance.yahoo.com logoEleven Biotherapeutics Announces Data and Safety Monitoring Board (DSMB) Recommendation to Continue Phase 3 Registration Trial with Vicinium™ in Non-Muscle Invasive Bladder Cancer Based on Review of Safety and Efficacy Data
finance.yahoo.com - June 1 at 5:36 PM
finance.yahoo.com logoEleven Biotherapeutics, Inc.: Fading performance but may be making a comeback?
finance.yahoo.com - May 26 at 5:26 PM
finance.yahoo.com logoETFs with exposure to Eleven Biotherapeutics, Inc. : May 26, 2017
finance.yahoo.com - May 26 at 5:26 PM
businesswire.com logoEleven Biotherapeutics Continues Expansion of Clinical ... - Business Wire (press release)
www.businesswire.com - May 17 at 4:54 PM
finance.yahoo.com logoEleven Biotherapeutics Continues Expansion of Clinical Development Team with Appointment of David Brooks, M.D., Ph.D., to Senior Vice President, Clinical Development
finance.yahoo.com - May 17 at 11:06 AM
americanbankingnews.com logoZacks Investment Research Upgrades Eleven Biotherapeutics Inc (EBIO) to "Hold"
www.americanbankingnews.com - May 16 at 6:26 PM
finance.yahoo.com logoETFs with exposure to Eleven Biotherapeutics, Inc. : May 15, 2017
finance.yahoo.com - May 15 at 4:39 PM
americanbankingnews.com logoShort Interest in Eleven Biotherapeutics Inc (EBIO) Drops By 11.9%
www.americanbankingnews.com - May 10 at 7:18 AM
finance.yahoo.com logoEleven Biotherapeutics, Inc. :EBIO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 8, 2017
finance.yahoo.com - May 8 at 4:46 PM
americanbankingnews.com logoEleven Biotherapeutics Inc (EBIO) Announces Earnings Results
www.americanbankingnews.com - May 8 at 3:36 PM
americanbankingnews.com logoEleven Biotherapeutics Inc (EBIO) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 5 at 7:38 PM
americanbankingnews.com logoEleven Biotherapeutics (EBIO) Getting Somewhat Positive Media Coverage, Study Shows
www.americanbankingnews.com - May 4 at 5:08 PM
finance.yahoo.com logoEleven Biotherapeutics Reports First Quarter 2017 Financial Results - Yahoo Finance
finance.yahoo.com - May 4 at 5:01 PM
finance.yahoo.com logoInvestor Network: Eleven Biotherapeutics, Inc. to Host Earnings Call
finance.yahoo.com - May 4 at 9:47 AM
finance.yahoo.com logoEleven Biotherapeutics Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 4 at 9:47 AM
finance.yahoo.com logoETFs with exposure to Eleven Biotherapeutics, Inc. : May 3, 2017
finance.yahoo.com - May 3 at 4:45 PM
finance.yahoo.com logoEleven Biotherapeutics to Report First Quarter 2017 Financial Results on Thursday, May 4, 2017 - Yahoo Finance
finance.yahoo.com - April 28 at 11:02 PM
finance.yahoo.com logoEleven Biotherapeutics to Report First Quarter 2017 Financial Results on Thursday, May 4, 2017
finance.yahoo.com - April 28 at 5:58 PM
americanbankingnews.com logoSomewhat Critical News Coverage Very Unlikely to Affect Eleven Biotherapeutics (EBIO) Stock Price
www.americanbankingnews.com - April 27 at 5:08 PM
americanbankingnews.com logoEleven Biotherapeutics (EBIO) Given Daily News Sentiment Score of 0.31
www.americanbankingnews.com - April 24 at 5:45 PM
finance.yahoo.com logoETFs with exposure to Eleven Biotherapeutics, Inc. : April 21, 2017
finance.yahoo.com - April 21 at 4:55 PM
americanbankingnews.com logoEleven Biotherapeutics (EBIO) Getting Positive News Coverage, Analysis Finds
www.americanbankingnews.com - April 19 at 10:07 AM
americanbankingnews.com logoEleven Biotherapeutics (EBIO) Receiving Critical Press Coverage, Analysis Finds
www.americanbankingnews.com - April 14 at 7:48 AM
streetinsider.com logoEleven Biotherapeutics (EBIO) Presents New Preclinical Data With ... - StreetInsider.com
www.streetinsider.com - April 4 at 7:07 AM
biz.yahoo.com logoELEVEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - April 4 at 7:07 AM
finance.yahoo.com logoEleven Biotherapeutics Presents New Preclinical Data at AACR Supporting the Potential of the Company’s Locally- and Systematically-Administered Drug Candidates
finance.yahoo.com - April 2 at 4:47 PM
finance.yahoo.com logoELEVEN BIOTHERAPEUTICS, INC. Financials
finance.yahoo.com - March 30 at 5:18 PM
streetinsider.com logoEleven Biotherapeutics (EBIO) to Present New Preclinical Data at AACR
www.streetinsider.com - March 28 at 12:04 PM
finance.yahoo.com logoEleven Biotherapeutics to Present New Preclinical Data at the American Association for Cancer Research Annual Meeting 2017
finance.yahoo.com - March 27 at 12:05 PM
finance.yahoo.com logo7:02 am Eleven Biotherapeutics will present preclinical data 'supporting the ongoing development of its locally- and systemically-administered drug candidates' at the AACR Annual Meeting 2017, on April 2
finance.yahoo.com - March 27 at 12:05 PM
baystreet.ca logoEleven Biotherapeutics (EBIO) Gains Ahead of Q4 Earnings
www.baystreet.ca - March 26 at 4:36 PM
finance.yahoo.com logoEleven Biotherapeutics Reports Fourth Quarter and Full Year 2016 Financial Results
finance.yahoo.com - March 24 at 9:40 AM
biz.yahoo.com logoQ4 2016 Eleven Biotherapeutics Inc Earnings Release - Time Not Supplied
biz.yahoo.com - March 24 at 9:40 AM
biz.yahoo.com logoELEVEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
biz.yahoo.com - March 24 at 9:40 AM
americanbankingnews.com logoEleven Biotherapeutics Inc (EBIO) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - March 24 at 9:17 AM
seekingalpha.com logoEleven Biotherapeutics (EBIO) Presents At Oppenheimer 27th Annual Healthcare Conference
seekingalpha.com - March 22 at 4:59 PM
finance.yahoo.com logoEleven Biotherapeutics to Report Fourth Quarter and Full Year 2016 Financial Results on Friday, March 24, 2017
finance.yahoo.com - March 22 at 4:59 PM
americanbankingnews.com logoEleven Biotherapeutics Inc (EBIO) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - March 21 at 7:34 AM
finance.yahoo.com logoEleven Biotherapeutics to Present at Oppenheimer's 27th Annual Healthcare Conference
finance.yahoo.com - March 20 at 7:44 PM

Social

Chart

Eleven Biotherapeutics (EBIO) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by MarketBeat.com Staff